Highest-materiality recent filing
Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B
Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.
Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
Oruka Therapeutics closes 9.66M-share offering at $72.50; prelim cash $496M
Oruka completed underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, raising gross proceeds of approximately $700 million.
Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing
Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.
Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones
Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.
Oruka Therapeutics enters exclusive IL-23 license with Paragon; up to $22M milestones
Oruka grants exclusive worldwide license for anti-IL-23 antibodies (ORKA-001) from Paragon, excluding inflammatory bowel disease.
Oruka raises $200M via PIPE; accelerates ORKA-001/002 clinical timelines
Gross proceeds of ~$200M from sale of common stock, preferred stock, and pre-funded warrants at $23.00 per common share.
ARCA completes reverse merger with Oruka; combined entity renamed Oruka Therapeutics (ORKA)
Merger closed: ARCA (shell) merges with private Oruka; Oruka shareholders own ~97.6% of combined company.
Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
ARCA biopharma declares special dividend of $1.59/share in connection with proposed Oruka merger
Special dividend estimated at $1.59 per share, payable to stockholders of record as of August 26, 2024.
ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing
Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.
ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed
Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.
ARCA biopharma boosts CEO and CFO retention bonuses to $200K each
Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.
CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President
Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.
ARCA biopharma to merge with Oruka; Oruka holders to own ~97.6% of combined company
Oruka stockholders to own ~97.62% of the combined company; ARCA stockholders ~2.38%.
ARCA biopharma reports Q3 2023 net loss of $1.4M; cash $38.5M sufficient through end of 2024
Net loss of $1.4M ($0.10/share) vs $2.3M ($0.16/share) in Q3 2022; operating expenses down to $2.0M from $2.6M.
ARCA biopharma Q2 2023 net loss $1.5M; cash $40.2M; strategic review continues
Net loss $1.5M ($0.10/sh) vs $3.1M ($0.22) in Q2 2022; total operating expenses $2.0M vs $3.2M.
ARCA biopharma reports Q1 net loss of $1.3M; strategic review ongoing
Net loss of $1.3M ($0.09 per share) vs $3.3M ($0.23) in Q1 2022; improvement due to lower R&D costs.
ARCA biopharma reports FY2022 net loss of $9.9M; cash $42.4M; strategic review ongoing
Net loss $9.9M ($0.69/share) vs $19.3M ($1.39/share) in 2021; operating expenses down to $10.6M from $19.3M.
ARCA biopharma elects James Flynn to Board; annual meeting results
James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.
ARCA biopharma Q2 net loss narrows to $3.1M; strategic review ongoing
Net loss $3.1M ($0.22/sh) vs $4.8M ($0.34/sh) year ago.
Jacob Ma-Weaver appointed as Class III director effective June 15, 2022, term through 2024 annual meeting.
ARCA biopharma retains Ladenburg Thalmann for strategic options review
Retained Ladenburg Thalmann & Co. Inc. as financial advisor for strategic review.
ARCA biopharma Q1 net loss narrows to $3.3M; initiates strategic review
Net loss of $3.3M ($0.23/share) vs $4.1M ($0.33/share) in Q1 2021, narrowing on lower R&D spend.
ARCA biopharma establishes Special Committee to evaluate strategic options
Special Committee formed to explore options for maximizing stockholder value.
ARCA biopharma's rNAPc2 fails to meet primary endpoint in Phase 2b COVID-19 trial
Pooled rNAPc2 reduced D-dimer 16.8% vs heparin 11.2% (P=0.47), missing statistical significance.
the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.
Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023.
On December 15, 2022, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) elected James Flynn, as a director of the Company.
On June 15, 2022, the Board of the Company elected Jacob Ma‐Weaver as a director of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material